Breaking News Instant updates and real-time market news.

KPTI

Karyopharm

$12.57

0.86 (7.34%)

07:29
11/04/19
11/04
07:29
11/04/19
07:29

Karyopharm expects topline data from Phase 3 BOSTON study in early 2020

Karyopharm's pivotal, randomized Phase 3 BOSTON study is progressing and patient enrollment was completed in January 2019. Top-line data are expected in early 2020 contingent upon the occurrence of progression-free survival events, the primary endpoint of the study. The BOSTON study is evaluating 100mg of selinexor dosed once weekly in combination with the proteasome inhibitor Velcade and low dose dexamethasone, compared to standard twice weekly Velcade and low dose dexamethasone in patients with multiple myeloma who have had one to three prior lines of therapy. Data from the BOSTON study, if positive, are expected to be used to support regulatory submissions to the FDA and EMA requesting the use of selinexor in combination with Velcade and dexamethasone in patients with multiple myeloma who have received at least one prior therapy.

  • 04

    Nov

  • 07

    Dec

KPTI Karyopharm
$12.57

0.86 (7.34%)

07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
Karyopharm upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst says his doctor survey supports a "strong" Xpovio launch and long-term outlook.
07/23/19
JPMS
07/23/19
UPGRADE
Target $16
JPMS
Overweight
JPMorgan upgrades Karyopharm after doctor survey, doubles price target
JPMorgan analyst Eric Joseph upgraded Karyopharm Therapeutics to Overweight from Neutral and doubled his price target for the shares to $16 from $8. The analyst conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months, Joseph tells investors in a research note. Importantly, nearly all respondents described the side-effect profile as manageable, which is "very encouraging," adds the analyst. He sees a favorable reward/risk profile for Karyopharm shares at current levels.
07/23/19
07/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Buy from Hold at Stifel with analyst John Egbert saying the company's sales reorganization efforts were already reflected in its prior guidance and the daily active user checks for the quarter appear to be positive. 2. Murphy Oil (MUR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Singer saying he believes the company's free cash flow generation is being underappreciated by the market. 3. Karyopharm (KPTI) upgraded to Overweight from Neutral at JPMorgan with analyst Eric Joseph saying he conducted a U.S. physician survey assessing Xpovio anticipated use in the approved indication of penta-refractory myeloma, as well as expectations around use in earlier-line settings. The survey of 15 doctors data show favorable reception to Xpovio's clinical profile, with 75% respondents intending to write Xpovio for PR-MM within the next 12 months. 4. Smith & Nephew (SNN) upgraded to Buy from Hold at Berenberg with analyst Tom Jones saying he believes management and process changes have addressed the company's execution issues. He views Smith & Nephew's portfolio as "highly competitive." 5. Columbia Sportswear (COLM) upgraded to Buy from Neutral at BofA/Merrill with analyst Alexander Perry citing his outlook for the company to generate "significant near-term revenue and EPS upside" amid a strong wholesale environment for Columbia's apparel as well as its "significant" under-penetration in footwear. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/24/19
BARD
09/24/19
NO CHANGE
Target $25
BARD
Outperform
Karyopharm Xpovio launch appears strong, says Baird
Baird analyst Michael Ulz said his physician survey regarding the Karyopharm launch of Xpovio is indicating strong early trends. The analyst said there appears to be an early robust, broad adoption with meaningful share gains ahead, and the safety profile is manageable. Ulz said he sees upside to estimates and he reiterated his Outperform rating and $25 price target on Karyopharm shares.

TODAY'S FREE FLY STORIES

MKC

McCormick

$170.70

-0.635 (-0.37%)

17:12
12/11/19
12/11
17:12
12/11/19
17:12
Initiation
McCormick initiated  »

McCormick resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$33.37

0.27 (0.82%)

17:10
12/11/19
12/11
17:10
12/11/19
17:10
Conference/Events
Continental Resources to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIS

General Mills

$51.57

-1.67 (-3.14%)

, K

Kellogg

$66.17

-0.48 (-0.72%)

17:08
12/11/19
12/11
17:08
12/11/19
17:08
Initiation
General Mills, Kellogg initiated  »

General Mills resumed…

GIS

General Mills

$51.57

-1.67 (-3.14%)

K

Kellogg

$66.17

-0.48 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CEI

Camber Energy

$2.05

0.86 (72.27%)

17:05
12/11/19
12/11
17:05
12/11/19
17:05
Hot Stocks
Camber Energy responds to unusual market activity »

Camber Energy commented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGEN

Miragen Therapeutics

$0.69

0.0554 (8.73%)

17:04
12/11/19
12/11
17:04
12/11/19
17:04
Conference/Events
Miragen Therapeutics to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGI

Alamos Gold

$5.57

0.205 (3.82%)

17:03
12/11/19
12/11
17:03
12/11/19
17:03
Hot Stocks
Alamos Gold sees FY20 production 425K-465K ounces of gold »

Alamos Gold provided 2020…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMNFF

MedMen

$0.00

(0.00%)

17:02
12/11/19
12/11
17:02
12/11/19
17:02
Earnings
MedMen sees positive adjusted EBITDA in Q121, and positive FCF in Q321 »

The company anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CPB

Campbell Soup

$48.00

-0.37 (-0.76%)

17:02
12/11/19
12/11
17:02
12/11/19
17:02
Initiation
Campbell Soup initiated  »

Campbell Soup resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MMNFF

MedMen

$0.00

(0.00%)

17:00
12/11/19
12/11
17:00
12/11/19
17:00
Earnings
MedMen sees FY20 revenue $225M - $245M, consensus $212.69M »

Sees FY21 revenue $450 -…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

XOM

Exxon Mobil

$68.95

-0.11 (-0.16%)

16:59
12/11/19
12/11
16:59
12/11/19
16:59
Hot Stocks
Exxon Mobil's Milton sells 13,569 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SJM

J.M. Smucker

$104.42

-1.64 (-1.55%)

16:57
12/11/19
12/11
16:57
12/11/19
16:57
Initiation
J.M. Smucker initiated  »

J.M. Smucker resumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

16:55
12/11/19
12/11
16:55
12/11/19
16:55
Conference/Events
Oppenheimer healthcare analysts to hold a KOL dinner meeting »

Analysts hold a Cardiac…

MMNFF

MedMen

$0.00

(0.00%)

16:54
12/11/19
12/11
16:54
12/11/19
16:54
Hot Stocks
MedMen granted delivery-only license by the city of Mountain View, California »

On November 21, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CAG

Conagra Brands

$28.64

-0.58 (-1.98%)

16:53
12/11/19
12/11
16:53
12/11/19
16:53
Initiation
Conagra Brands initiated  »

Conagra Brands resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

EQH

AXA Equitable

$24.27

-0.18 (-0.74%)

16:53
12/11/19
12/11
16:53
12/11/19
16:53
Hot Stocks
AXA Equitable sells two run-off and closed-block companies »

AXA Equitable has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

MMNFF

MedMen

$0.00

(0.00%)

16:50
12/11/19
12/11
16:50
12/11/19
16:50
Hot Stocks
MedMen announces financial updates to strengthen balance sheet »

MedMen Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

MDLZ

Mondelez

$53.94

-0.13 (-0.24%)

16:48
12/11/19
12/11
16:48
12/11/19
16:48
Initiation
Mondelez initiated  »

Mondelez resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.04

0.01 (0.25%)

16:42
12/11/19
12/11
16:42
12/11/19
16:42
Hot Stocks
Encana to establish corporate domicile in U.S. »

Encana filed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$10.98

-0.02 (-0.18%)

16:41
12/11/19
12/11
16:41
12/11/19
16:41
Upgrade
Analyst change prompts UBS to upgrade GE to Buy from Neutral »

UBS analyst Markus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 29

    Jan

HSY

Hershey

$149.81

0.415 (0.28%)

16:40
12/11/19
12/11
16:40
12/11/19
16:40
Initiation
Hershey initiated  »

Hershey resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$167.47

1.72 (1.04%)

16:39
12/11/19
12/11
16:39
12/11/19
16:39
Earnings
Nordson sees FY20 GAAP EPS growth 2%--6% versus FY19 »

"We are taking a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

WHLR

Wheeler REIT

$1.79

-0.09 (-4.79%)

16:38
12/11/19
12/11
16:38
12/11/19
16:38
Hot Stocks
Wheeler REIT nominees recommended by Glass Lewis »

Wheeler REIT announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

HD

Home Depot

$211.96

-3.88 (-1.80%)

, BA

Boeing

$350.00

2.14 (0.62%)

16:38
12/11/19
12/11
16:38
12/11/19
16:38
On The Fly
Fly Intel: Wall Street's top stories for Wednesday »

The Federal Reserve did…

HD

Home Depot

$211.96

-3.88 (-1.80%)

BA

Boeing

$350.00

2.14 (0.62%)

CVX

Chevron

$116.22

-1.68 (-1.42%)

GME

GameStop

$5.53

-0.97 (-14.92%)

NSRGY

Nestle

$0.00

(0.00%)

MD

Mednax

$26.75

1.975 (7.97%)

OLLI

Ollie's Bargain Outlet

$69.39

9.11 (15.11%)

LOGM

LogMeln

$79.82

5.86 (7.92%)

PLAY

Dave & Buster's

$38.59

-1.48 (-3.69%)

UNFI

United Natural Foods

$7.07

-2.81 (-28.44%)

PLCE

Children's Place

$54.35

-16.32 (-23.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 11

    Dec

  • 13

    Dec

  • 18

    Dec

  • 25

    Feb

NDSN

Nordson

$167.47

1.72 (1.04%)

16:35
12/11/19
12/11
16:35
12/11/19
16:35
Hot Stocks
Nordson says backlog for the quarter was approximately $385M, down 1% YoY »

Backlog for the quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

GAIN

Gladstone Investment

$14.65

-0.02 (-0.14%)

, CPTA

Capitala Finance

$8.74

0.16 (1.86%)

16:35
12/11/19
12/11
16:35
12/11/19
16:35
Hot Stocks
Gladstone Investment exits investment in Nth Degree »

Gladstone Investment…

GAIN

Gladstone Investment

$14.65

-0.02 (-0.14%)

CPTA

Capitala Finance

$8.74

0.16 (1.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.